Top Markets
#1 Black Phoenix Black Phoenix +733.82%
#2 MiL.k Alliance MiL.k Alliance +29.84%
#3 Biconomy Biconomy +24.27%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.03%
#5 THORChain THORChain +19.51%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +15.95%
#7 Moolah Moolah +14.73%
#8 THORChain Yield THORChain Yield +14.31%
#9 Tokamak Network Tokamak Network +12.76%
#10 XPIN Network XPIN Network +12.32%
Coin of the day
Black Phoenix Black Phoenix
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Hybio Pharmaceutical Co., Ltd. Hybio Pharmaceutical Co., Ltd.

Hybio Pharmaceutical Co., Ltd.

300199
Rang în acțiuni #5169
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Preț acțiune
$3.32
Capitalizare de piață
$2.93B
Schimbare (1 zi)
1.10%
Schimbare (1 an)
-8.99%
Țară
CN
Tranzacționează Hybio Pharmaceutical Co., Ltd. (300199)

Categorie

Healthcare
Venituri pentru Hybio Pharmaceutical Co., Ltd. (300199)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Hybio Pharmaceutical Co., Ltd., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Hybio Pharmaceutical Co., Ltd. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN